The rate-limiting step for de novo actin filament assembly is nucleation, which requires the formation of actin dimers and trimers (reviewed in [1] 
Here, we characterized the activity of full-length Las17 nM [19] ). In addition, Las17 activity was dramatically stronger than its carboxyl terminus alone (WA domain). on Arp2/3 complex in the presence and absence of two Las17 ligands, Bbc1 and Sla1. Las17 had constitutive
In contrast, concentrations of full-length Las17 that strongly stimulated actin assembly in the presence of activity (nonautoinhibited) and was negatively regulated by Bbc1 and Sla1. Thus, Las17 function is controlled by Arp2/3 complex had no effect on the assembly rate of actin alone ( Figure 2B ). inhibitory ligands and in this way behaves more like SCAR/WAVE than WASp proteins.
Since the WA domain used in Figure 2A was purified from E. coli, while full-length Las17 was purified from yeast, we considered the possibility that activity differResults and Discussion ences might be due to the expression source. Therefore, we purified from yeast a carboxyl-terminal 106 amino Purified Full-Length Las17 Is Highly Active and Is Not Autoinhibited acid fragment of Las17 by the same method used to purify full-length Las17. This WA domain had a similar To investigate the regulation of Las17 activity, we purified full-length Las17 protein from yeast overexpressing activity to the WA domain purified from E. coli (not shown), suggesting that the strong activity of Las17 is Las17 fused to nine repeats of the myc epitope tag. The tagged Las17 was affinity purified by using anti-myc not due to its expression source, or to the residual amino acids left on the recombinant protein after cleavage from antibody-coated beads, and the tag was cleaved by TEV protease digestion, leaving the sequence AAAENLYFQ the myc epitope tag. These data suggest that Las17 sequences amino terminal to the WA domain play an appended to the carboxyl terminus of Las17 (Figure 1) . We tested the activity of Las17 on actin assembly in the important role in Arp2/3 complex activation. presence and absence of purified yeast Arp2/3 complex.
In contrast to other WASp family members, Las17 was
Effects of Profilin on Las17-Arp2/3 Complex-Induced Actin Filament Nucleation not autoinhibited (Figure 2A ). Full-length Las17 potently activated Arp2/3 complex with half-maximal activation Profilin is an actin monomer binding protein that sterically blocks assembly of actin monomers onto the at 4.2 nM ( Figures 2B and 2C Figure 3A) . We used this observation to test whether activation of Arp2/3 complex by full-length Las17 works by a different mechanism than WA domain activation of Arp2/3 complex. Concentrations of profilin that strongly inhibited maximal WA domain activation of Arp2/3 complex had no effect on full-length Las17-mediated actin assembly ( Figure 3A) . Since Las17 contains several putative profilin binding poly-proline sequences, we tested whether direct binding of profilin to Las17 might alleviate the negative effects of profilin on actin assembly. Arp2/3 complex stimulation by Las17 was tested in the presence of a mutant profilin (Pfy1-19, containing the mutation Y120D) that has at least ten-fold reduced polyproline binding [20] Figure 3A ). These data suggest that Las17-profilin binding does not alleviate inhibition of actin assembly by profilin. One caveat to this interpretation is that Pfy1 and Pfy1-19 may have a much higher affinity for Las17 than for poly-proline, since mammalian profilin-I has a higher affinity for N-WASp than for poly-proline [22] . However, no association has yet been detected between Las17 and profilin in multiple efforts to find Las17-interacting partners (e.g., [10, 15, 23]).
Arp2/3 complex activation is thought to be mediated by a combination of two inputs: conformational change induced by binding of Arp2/3 complex to the sides of actin filaments, and conformational change induced by activator binding (reviewed in [2]). To explain the effects of profilin on WA-Arp2/3 complex, we considered the possibility that by preventing spontaneous formation of actin filaments at early stages of assembly, profilin might inhibit WA-mediated Arp2/3 complex activation. To test this model, we added preformed actin filaments to WAactivated Arp2/3 complex. While preformed filaments eliminated the lag phase of actin polymerization, they did not overcome the inhibitory effects of profilin ( Figure  3B) . The SH3 domain-containing fragment of Sla1 proved to be significantly more amenable to purification and manipulation than full-length Sla1, and since both Sla1 constructs had similar activity on Las17-Arp2/3 complex (not shown), only data using the Sla1 fragment (referred to as Sla1SH3) are shown. Bbc1 also had an inhibitory activity on Las17; 150 nM Bbc1 inhibited Las17 activation of Arp2/3 complex by 28% ( Figure 4B ). The combination of Sla1SH3 and Bbc1 together had a more pronounced effect (63% maximum, Figure 4B ) than could be achieved by using Sla1 alone. By comparison, Sla1SH3 and Bbc1 had no effect on WA-Arp2/3 complex activity, indicating that their effects require sequences in Las17 amino terminal to the WA domain. We were unable to purify sufficient amounts of Bbc1 to saturate its inhibitory effect on Las17. However, 250 nM Bbc1 had an equally strong additive effect with both subsaturating (0.5 M) and saturating (2 M) amounts of Sla1SH3 (see the Supplemental Data available with this article online). This suggests that Sla1 and Bbc1 act through distinct binding sites on Las17. 200 nM Abp1 with mutated acidic sequences (and thus unable to stimulate Arp2/3 complex [34]), but with an intact SH3 domain, had no effect on Las17 activation of Arp2/3 complex (not shown). Thus, the activities of Sla1 and Bbc1 on Las17 require specific SH3 domain interactions.
To define which SH3 domain(s) in Sla1 are required for inhibition of Las17-Arp2/3 complex, we generated point mutations in the conserved tryptophan residues of each of the three Sla1 SH3 domains (W41A, W108A, and W391A). These types of mutations have been shown to abolish SH3 domain interactions with proline-rich targets [35] . Inactivation of either the first (Sla1SH3-1*) or second (Sla1SH3-2*) SH3 domain of Sla1 alone diminished the inhibition of Las17 ( Figure 4C) . Disruption of the first and second SH3 domains together (Sla1SH3-1ϩ2*) inactivated Sla1 to a similar extent as disruption of either SH3 domain alone. In contrast, disruption of Our data support the model that there is a shared in We generated sla1⌬ bbc1⌬ double mutants and found vivo function for Sla1 and Bbc1 mediated by the first that they were viable at room temperature but were more two SH3 domains of Sla1 ( Figure 5 ). Our genetic data temperature sensitive at 34ЊC and 37ЊC than either single correlate with the biochemical data showing that the mutant (data not shown). Low-copy plasmids were used first and second SH3 domains of Sla1 are required for to express full-length sla1 mutants with SH3 domain its inhibitory activity on Las17 ( Figure 4C ). In previous disruptions that impair activities on Las17 in vitro. Mutastudies, no role was found for Sla1 SH3 domains in tion of any combination of SH3 domains of SLA1 in rescuing the sla1 null phenotype or the synthetic lethality otherwise wild-type cells had no effect on cell growth or between sla1 and abp1 [30]. Thus, our data define the actin organization (not shown); this finding is consistent first in vivo function for the SH3 domains of Sla1 and with previous studies [30] . However, mutation of either suggest that the first two SH3 domains of Sla1 in combithe first or second SH3 domains of SLA1 in combination nation with Bbc1 negatively regulate Las17. with the bbc1⌬ null mutation reduced growth at 37ЊC, and mutation of both of these SLA1 SH3 domains in combination with bbc1⌬ caused lethality at 37ЊC ( Figure  Function 
and Regulation of Las17 In Vivo
We have shown that Las17 has a much stronger ability 5A). These double mutant cells were large and round, which is a phenotype common for mutants in actinto activate Arp2/3 complex than its carboxyl-terminal WA fragment and that full-length Las17 purified from associated proteins ( Figure 5B) [37]. In contrast, mutation of the third SH3 domain of SLA1 in bbc1⌬ cells had yeast by the method described here is not autoinhibited. Since mammalian WASp, for unknown reasons, can be no effect. We examined actin organization in sla1 bbc1⌬ cells by rhodamine phalloidin staining. In SLA1 bbc1⌬ purified in both inhibited and uninhibited forms [4, 38], it remains possible that Las17 might be autoregulated cells, cortical actin patches are polarized in the bud. Mutation of either the first or second SH3 domains of under certain conditions. However, the absence of a G protein binding motif in Las17 is more consistent with SLA1 in bbc1⌬ cells had no discernable effect on cortical actin patch actin organization, but the sla1SH3-1ϩ2* it being regulated by a mechanism similar to that reported for SCAR/WAVE than for WASp proteins. This mutation resulted in large, aberrant filamentous actin clumps, similar to the sla1⌬ bbc1⌬ double mutant phealso raises the possibility that WASp proteins in other organisms may be subject to negative regulation. Renotype ( Figure 5B ). This actin phenotype is much more severe than that of sla1⌬ BBC1 cells (data not shown gardless of whether Las17 can be autoinhibited, our genetic and biochemical data define a combined inhibiand [30]). All SLA1 mutants fully complement the phenotype of the sla1⌬ null mutant (not shown), indicating that tory function for Sla1 and Bbc1 on Las17-Arp2/3 complex and the first in vivo function for Sla1 SH3 domains. the mutant proteins are expressed.
To confirm that the shared function of SLA1 and BBC1 What is the specific function of Las17 in cells? Localization of Las17, myosin I, and Vrp1 to cortical patches was not simply localization of Las17 to actin structures, we examined Las17-GFP localization in bbc1⌬ sla1SH3-is maintained after treatment of cells with latrunculin-A, an actin monomer-sequestering agent that leads to net 1ϩ2* cells. Las17-GFP colocalized with actin in large, aberrant clumps ( Figure 5C) 
